Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
MG-262 (Z-Leu-Leu-Leu-B(OH)2): Precision in Proteasome Inhib
2026-05-19
MG-262 (Z-Leu-Leu-Leu-B(OH)2) brings unmatched control to proteasome inhibition assays, enabling highly reproducible apoptosis and cell cycle arrest research. With reversible, nanomolar potency and robust cell permeability, it stands apart for dissecting protein degradation mechanisms in complex models.
-
MG-132 (Z-LLL-al): Benchmarks for Proteasome Inhibition Rese
2026-05-19
MG-132 (Z-LLL-al) is a potent, cell-permeable peptide aldehyde proteasome inhibitor that selectively targets the ubiquitin-proteasome system in eukaryotic cells. It induces apoptosis, cell cycle arrest, and oxidative stress, with validated applications in cancer research and mechanistic studies of protein homeostasis. This article provides evidence-backed benchmarks, protocol guidance, and clarifies common misconceptions for MG-132 experimental use.
-
Adipose-Neural Axis in Cardiac Arrhythmias: Mechanistic Insi
2026-05-18
This article reviews Fan et al.'s mechanistic study showing how adipocyte-derived leptin activates sympathetic neurons to trigger cardiac arrhythmias via neuropeptide Y (NPY) signaling and downstream targets. Their coculture model provides new experimental and therapeutic perspectives for understanding epicardial adipose tissue's role in arrhythmogenesis.
-
CD44-Mediated Metabolic Rewiring in IDH-Mutant AML: A Target
2026-05-18
This study uncovers how CD44 upregulation in IDH-mutant leukemia rewires cellular metabolism to sustain pathological 2-hydroxyglutarate (R-2HG) production, revealing a critical metabolic dependency. Targeting the CD44-driven pathway presents a promising therapeutic vulnerability, with direct implications for refining strategies in acute myeloid leukemia research.
-
ML-7 Hydrochloride: Mechanistic Foundations and Next-Gen Ass
2026-05-17
Explore the mechanistic foundations of ML-7 hydrochloride as a myosin light chain kinase inhibitor, with deep analysis of its implications for advanced cardiovascular and endothelial research. This article uniquely connects molecular action to practical assay strategy.
-
Carboxylesterase Interference in Amplex Red Mitochondrial H2
2026-05-16
Miwa et al. (2016) revealed that carboxylesterases can directly convert Amplex Red to resorufin, independent of H2O2, challenging the specificity of a widely used mitochondrial hydrogen peroxide assay. Their findings highlight the need for methodological refinement in reactive oxygen species measurement, with critical implications for the interpretation of oxidative stress data in basic and translational research.
-
MG-132 in Cancer Research: Protocols, Precision, and Insight
2026-05-15
MG-132 (Z-LLL-al) stands at the forefront of proteasome inhibition, empowering apoptosis assays and cell cycle arrest studies with unparalleled specificity. This guide delivers data-driven workflows, troubleshooting strategies, and translational context for maximizing reproducibility and sensitivity in cancer research.
-
Exo1: Precision Membrane Trafficking Inhibition in Exocytosi
2026-05-15
Exo1 (methyl 2-(4-fluorobenzamido)benzoate) enables acute, mechanism-distinct inhibition of Golgi-to-ER trafficking, empowering advanced exocytic pathway research and high-fidelity exocytosis assays. Its selectivity for ARF1 release—without disrupting the trans-Golgi network—offers unique experimental control and interpretability in tumor extracellular vesicle studies.
-
KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyros
2026-05-14
KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine delivers selective, high-potency CaMKII inhibition, enabling rigorous dissection of calcium signaling, insulin regulation, and cell cycle control. This guide translates bench-validated workflows and expert troubleshooting into actionable lab protocols, leveraging APExBIO’s trusted formulation for reproducible results.
-
ACSF3 Variant Drives Human Height and Metabolic Rate Evoluti
2026-05-14
Zhang et al. identify a regulatory variant (rs34590044-A) that upregulates ACSF3, simultaneously increasing human height and basal metabolic rate (BMR). This study reveals how metabolic homeostasis links genetic adaptation, dietary shifts, and key human phenotypes, with direct implications for metabolic and evolutionary biology.
-
Isradipine (Dynacirc) in Neuroprotection & Vascular Research
2026-05-13
Isradipine (Dynacirc) from APExBIO stands out as a high-purity, research-grade L-type calcium channel blocker, enabling precise interrogation of calcium-mediated processes in neurodegeneration and vascular smooth muscle function. This guide delivers actionable protocols, troubleshooting insights, and comparative context for scientists deploying isradipine in cutting-edge excitotoxicity and hypertension research.
-
2,5-di-tert-butylbenzene-1,4-diol (BHQ) in Calcium Signaling
2026-05-13
2,5-di-tert-butylbenzene-1,4-diol (BHQ) unlocks precise control over calcium homeostasis via selective SERCA inhibition, enabling advanced studies in hematopoietic stem cell mobilization and calcium signaling. This article delivers protocol enhancements, troubleshooting insight, and applied strategies for maximizing the translational impact of BHQ in both basic and preclinical workflows.
-
ML133 HCl: Precision Tool for Decoding Kir2.1 Channel Functi
2026-05-12
Explore how ML133 HCl, a selective potassium channel inhibitor, revolutionizes pulmonary artery smooth muscle cell proliferation research. This article unveils advanced assay strategies and practical insights unavailable elsewhere.
-
DNA Hypomethylation Reactivates TCN1 Autoantigen in Psoriasi
2026-05-12
This study identifies transcobalamin 1 (TCN1) as a novel keratinocyte-derived autoantigen in psoriasis, reactivated by DNA hypomethylation and driving T helper 17 cell activation. The findings highlight a mechanistic link between epigenetic deregulation and autoimmune inflammation, offering new avenues for both biomarker discovery and therapeutic intervention.
-
BHQ (2,5-di-tert-butylbenzene-1,4-diol): Beyond SERCA Inhibi
2026-05-11
Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) enables precise modulation of calcium homeostasis and advances hematopoietic stem cell mobilization strategies. This article delivers new, evidence-based insights into BHQ’s mechanism and translational value, distinct from existing overviews.
14830 records 8/989 page Previous Next First page 上5页 678910 下5页 Last page